Zydus Cadila receives approval from USFDA for Arsenic Trioxide Injection

14 Nov 2018 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dose vial (US RLD -TRISENOX). It will be manufactured at Alidac Pharmaceuticals, the company's wholly-owned subsidiary located at SEZ, Ahmedabad.  Arsenic Trioxide is used to treat a type of leukemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.

The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

890.50 -2.95 (-0.33%)
28-Jan-2026 09:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1632.35
Dr. Reddys Lab 1233.60
Cipla 1314.10
Zydus Lifesciences 890.50
Lupin 2142.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×